Drug profile · INN
phenylbutazone
AZOLID
- US status
- approved
- Patents linked
- 8
- News articles
- 0
Quick answer
phenylbutazone (AZOLID) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 11542275
Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors
granted -
US 11365205
Imidazolidin-2-one compounds as PRMT5 modulators
granted -
US 10709692
Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
granted -
US 10544113
Thiazolidinone compounds and use thereof
granted -
US 9060941
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
granted -
US 8637560
Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
granted -
US 8404650
Methods of treating cancer with doxazolidine and prodrugs thereof
granted -
US 8283370
Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use
granted
Frequently asked questions
What is phenylbutazone?
phenylbutazone (AZOLID) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for phenylbutazone?
AZOLID is a marketed brand name for phenylbutazone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of phenylbutazone?
phenylbutazone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.